Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Australia thrashes out patient access deals for Soliris/Kalydeco

This article was originally published in Scrip

Executive Summary

The Australian authorities are to start funding the use of Alexion's Soliris (eculizumab) for atypical hemolytic uremic syndrome (aHUS) and Vertex' Kalydeco (ivacaftor) for cystic fibrosis under the Pharmaceutical Benefits Scheme (PBS) from 1 December.

You may also be interested in...



Cystic Fibrosis: Successes, Opportunities And Challenges

What is next for the treatment of cystic fibrosis, a rare disease market that has boomed in recent years on the back of new drug approvals with hefty price tags? Pipelines are full, but securing reimbursement is a challenge.

EU Review Proposals ‘Fail To Analyze’ Impact Of Reduced Exclusivity Periods

Plans for the overhaul of the EU’s medicines framework are missing key analysis on the effect of reductions in data and market protection on the pharmaceutical industry, despite an abundance of studies on how such incentives influence company decisions on whether to develop new products, say lawyers from Sidley.

EU Commission Again Delays Pharma Revision Proposals, Citing ‘Busy Agenda’

Two members of the European Parliament claim the latest delay to publication of the long-awaited legislative revision is the result of pressure from the pharmaceutical industry.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC026792

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel